The DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Tau Kinetics in Neurons and the Human Central Nervous System
Open accessAbstract
We developed stable isotope labeling and mass spectrometry approaches to measure the kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) and in human induced pluripotent stem cell (iPSC)-derived neurons. Newly synthesized tau is truncated and released from human neurons in 3 days. Although most tau proteins have similar turnover, 4R tau isoforms and phosphorylated forms of tau exhibit faster turnover rates, suggesting unique processing of these forms that may have independent biological activities. The half-life of tau in control human iPSC-derived neurons is 6.74 ± 0.45 days and in human CNS is 23 ± 6.4 days. In cognitively normal and Alzheimer's disease participants, the production rate of tau positively correlates with the amount of amyloid plaques, indicating a biological link between amyloid plaques and tau physiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“One of the significant hurdles in modeling AD with iPSC-derived neurons or NGN2-induced neurons for the past decade has been their inability to produce the 4R Tau isoform found in adult human brains [19–22]; only the fetal 0N3R splicing isoform is produced, even after one year of differentiation [19].”
From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [22]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, fetal neurons and iPSCs-derived neurons primarily express 3R-tau (20, 21)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF tau species precede tau positron emission tomography (PET) abnormalities by a decade.18,19”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, in relation to sporadic AD, this study adds further support to the hypothesis that CSF p-tau is closely related to Aβ-mediated tau release from neurons19 and challenges the notion of being simply a state marker of NFT.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sato et al36 report that in the human central nervous system, P-tau exhibits a faster turnover rate, which likely explains the elevated CSF level of this protein in various neurodegenerative conditions.”
From Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia (2020) · cites this paper as [36]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“This is important because little 4R tau is expressed in induced pluripotent stem cell (iPSC)-derived models without a splice-site mutation (lovino et al., 2015; Sato et al., 2018; Sposito et al., 2015; Verheyen et al., 2018).”
From ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids (2021) · cites this paper as Sato et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“Instead, evidence now documents active secretion of tau in normal and disease conditions.19,65”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252
Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110
Trans-Synaptic Spread of Tau Pathology In Vivo
Liu, L., Drouet, V., Wu, J., Witter, M. P., Small, S. A., Clelland, C. L. T., & Duff, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031302 · Cited by 994
Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., Barker, S. J., Foley, A. C., Thorpe, J. R., Serpell, L. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.047 · Cited by 986
Self-citationCorrection for partial volume effects in PET: principle and validation.
ROUSSET, O. G., Ma, Y., & Evans, A. C. (1998) · PubMed · Cited by 919
Neuronal activity enhances tau propagation and tau pathology in vivo
Wu, J. W., Hussaini, S. A., Bastille, I. M., Rodriguez, G. A., Mrejeru, A., Rilett, K., Sanders, D. W., Cook, C., Fu, H., Boonen, R. A. C. M., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4328 · Cited by 820
Biernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796
Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Self-citationIba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2642-12.2013 · Cited by 664
Physiological release of endogenous tau is stimulated by neuronal activity
Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W., & Hanger, D. P. (2013) · The EMBO Reports · doi:10.1038/embor.2013.15 · Cited by 642
Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., Takada, N., Inoue, M., Hasegawa, M., Kawamata, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103509108 · Cited by 628
Neuronal activity regulates extracellular tau in vivo
Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., Cirrito, J. R., Patel, T. K., Hochgräfe, K., Mandelkow, E., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131685 · Cited by 606
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationYanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574
Trans-cellular Propagation of Tau Aggregation by Fibrillar Species
Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346072 · Cited by 552
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Self-citationTau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 455
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450
Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Self-citationPhosphorylation determines two distinct species of tau in the central nervous system
Papasozomenos, S. C., & Binder, L. I. (1987) · Cell Motility · doi:10.1002/cm.970080303 · Cited by 420
The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology
Carmel, G., Mager, E. M., Binder, L. I., & Kuret, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32789 · Cited by 413
Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses
Mandelkow�, E. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.007 · Cited by 412
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
LoPresti, P., Szuchet, S., Papasozomenos, S. C., Zinkowski, R. P., & Binder, L. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10369 · Cited by 388
Hanger, D. P., Betts, J. C., Loviny, T. L. F., Blackstock, W. P., & Anderton, B. H. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062465.x · Cited by 386
Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau)
Dickson, D. W., Kouri, N., Murray, M. E., & Josephs, K. A. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9589-0 · Cited by 380
Analysis of proteome dynamics in the mouse brain
Price, J. C., Guan, S., Burlingame, A., Prusiner, S. B., & Ghaemmaghami, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006551107 · Cited by 357
Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E.-M., Diamond, M. I., Lee, V. M.-Y., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2569-11.2011 · Cited by 351
Antisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311
Self-citationTau truncation during neurofibrillary tangle evolution in Alzheimer’s disease
Guillozet-Bongaarts, A. L., Garcia-Sierra, F., Reynolds, M. R., Horowitz, P. M., Fu, Y., Wang, T., Cahill, M. E., Bigio, E. H., Berry, R. W., & Binder, L. I. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.019 · Cited by 256
Trabzuni, D., Wray, S., Vandrovcova, J., Ramasamy, A., Walker, R., Smith, C., Luk, C., Gibbs, J. R., Dillman, A., Hernandez, D. G., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds238 · Cited by 252
Partial volume correction in quantitative amyloid imaging
Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247
Self-citationQuantitative Analysis of PiB-PET with FreeSurfer ROIs
Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246
Self-citationLuo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241
Constitutive secretion of tau protein by an unconventional mechanism
Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 238
Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
Self-citationHuman secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230
Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease
Horowitz, P. M., Patterson, K. R., Guillozet-Bongaarts, A. L., Reynolds, M. R., Carroll, C. A., Weintraub, S. T., Bennett, D. A., Cryns, V. L., Berry, R. W., & Binder, L. I. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1988-04.2004 · Cited by 215
Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Szendrei, G., Lee, V. M. Y., & Otvos, L. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490340212 · Cited by 204
A role for tau at the synapse in Alzheimer’s disease pathogenesis
Pooler, A. M., Noble, W., & Hanger, D. P. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.018 · Cited by 203
Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules
Ferreira, A., & Cáceres, A. (1991) · Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00392.1991 · Cited by 203
Age and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
Self-citationExtracellular Tau Levels Are Influenced by Variability in Tau That Is Associated with Tauopathies
Karch, C. M. M., Jeng, A. T., & Goate, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380642 · Cited by 185
Self-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Self-citationPseudophosphorylation of tau protein alters its ability for self‐aggregation
Haase‐Kohn, C., Stieler, J., Arendt, T., & Holzer, M. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02287.x · Cited by 180
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180
AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure
Mishra, S., Gordon, B. A., Su, Y., Christensen, J. J., Friedrichsen, K. A., Jackson, K., Hornbeck, R. C., Balota, D. A., Cairns, N. J., Morris, J. C., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.050 · Cited by 178
Self-citationKanmert, D., Cantlon, A., Muratore, C., Jin, M., O’Malley, T. T., Lee, G. S., Young‐Pearse, T. L., Selkoe, D. J., & Walsh, D. M. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0387-15.2015 · Cited by 169
Liu, C., Song, X., Nisbet, R. M., & Götz, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641902 · Cited by 156
Derisbourg, M. J., Leghay, C., Chiappetta, G., Fernández-Gómez, F.-J., Laurent, C., Demeyer, D., Carrier, S., Buée‐Scherrer, V., Blum, D. L., Vinh, J., et al. (2015) · Scientific Reports · doi:10.1038/srep09659 · Cited by 149
Sposito, T., Preza, E., Mahoney, C. J., Setó-Salvia, N., Ryan, N. S., Morris, H. R., Arber, C., Devine, M. J., Houlden, H., Warner, T. T., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv246 · Cited by 148
Zempel, H., Dennissen, F. J. A., Kumar, Y., Luedtke, J., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784702 · Cited by 147
Morita, T., & Sobue, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008177 · Cited by 145
FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease
Mair, W., Muntel, J., Tepper, K., Tang, S., Biernat, J., Seeley, W. W., Kosik, K. S., Mandelkow�, E., Steen, H., & Steen, J. A. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04509 · Cited by 144
Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus
Desikan, R. S., Schork, A. J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L. K., Holland, D., Brewer, J. B., Chen, C., Thompson, W. K., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.6 · Cited by 142
Barthélemy, N. R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01001 · Cited by 123
Self-citationDistinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111
Silva, M. C., Cheng, C., Mair, W., Almeida, S., Fong, H., Biswas, M. H. U., Zhang, Z., Huang, Y., Temple, S., Coppola, G., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.001 · Cited by 103
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy
Borroni, B., Gardoni, F., Parnetti, L., Magno, L., Malinverno, M., Saggese, E., Calabresi, P., Spillantini, M. G., Padovani, A., & Luca, M. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.009 · Cited by 101
International FTD-Genomics Consortium (IFGC), Yokoyama, J. S., Karch, C. M., Fan, C. C., Bonham, L. W., Kouri, N., Ross, O. A., Rademakers, R., Kim, J., Wang, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1693-y · Cited by 99 · cited 1×
“Furthermore, a common haplotype in the MAPT gene, termed H1, is associated with increased risk for PSP, CBD, FTD, and AD, andMAPTH1 is also associated with altered expression of tau isoforms (Baker et al., 1999; Desikan et al., 2015; Trabzuni et al., 2012; Yokoyama et al., 2017).”
Self-citationEhrlich, M., Hallmann, A.-L., Reinhardt, P., Araúzo-Bravo, M. J., Korr, S., Röpke, A., Psathaki, O. E., Ehling, P., Meuth, S. G., Oblak, A. L., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.06.001 · Cited by 94
Combs, B., Hamel, C., & Kanaan, N. M. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.016 · Cited by 93
Self-citationN-Terminal Fragments of Tau Inhibit Full-Length Tau Polymerization in Vitro
Horowitz, P. M., LaPointe, N. E., Guillozet-Bongaarts, A. L., Berry, R. W., & Binder, L. I. (2006) · Biochemistry · doi:10.1021/bi061325g · Cited by 89
Analysis of in vivo turnover of tau in a mouse model of tauopathy
Yamada, K., Patel, T. K., Hochgräfe, K., Mahan, T. E., Jiang, H., Stewart, F. R., Mandelkow, E., & Holtzman, D. M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0052-5 · Cited by 79
Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry
Portelius, E., Hansson, S., Tran, A. J., Zetterberg, H., Grognet, P., Vanmechelen, E., Höglund, K., Brinkmalm, G., Brinkmalm, A., Nordhoff, E., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr7008669 · Cited by 79
McAvoy, T., Lassman, M. E., Spellman, D. S., Ke, Z., Howell, B. J., Wong, O., Lan, Z., Tanen, M., Struyk, A. F., & Laterza, O. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.216515 · Cited by 75
Liu, W. ‐., Moore, W. T., Williams, R. T., Hall, F. L., & Yen, S.-H. C. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490340315 · Cited by 60
In vivo kinetic approach reveals slow SOD1 turnover in the CNS
Crisp, M. J., Mawuenyega, K. G., Patterson, B. W., Reddy, N. C., Chott, R. C., Self, W. K., Weihl, C. C., Jockel, J., Varadhachary, A. S., Bucelli, R. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80705 · Cited by 59
Self-citationSun, Q., & Gamblin, T. C. (2009) · Biochemistry · doi:10.1021/bi900602h · Cited by 54
Barthélemy, N. R., Bateman, R. J., Marin, P., Bécher, F., Sato, C., Lehmann, S., & Gabelle, A. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/226977 · Cited by 16
Self-citation
Flagged first, then by citations
1 of the 82 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Metadata
- Authors
- Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., Kanaan, N. M., Yarasheski, K. E., Baker-Nigh, A., Benzinger, T. L. S., Miller, T. M., Karch, C. M., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Michigan State University (US)
- Corresponding author
- Sato, Chihiro
- Karch, Celeste M.
- Bateman, Randall J.
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 97
- Issue
- 6
- Pages
- 1284-1298.e7
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC6137722
- OpenAlex
- W2794390181
- Cited by
- 586
- References
- 82
- Citations by year
- 2026: 44 · 2025: 64 · 2024: 60 · 2023: 68 · 2022: 84 · 2021: 90 · 2020: 81 · 2019: 70 · 2018: 24
- FWCI
- 45.72
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-05-16)
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 385 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- BrightFocus Foundation (A2014384S)
- Tau SILK Consortium
- NIH (R01NS095773, R01NS078398, K01 AG046374, P30DK056341, P01AG003991, UL1TR000448, P30NS098577, P01AG026276, K01 AG053474, P50AG005681, P41GM103422, P30DK020579)
- MetLife Foundation
- Knight ADRC (P50AG05681)
- Coins for Alzheimer’s Research Trust
- Barnes-Jewish Hospital Foundation (UL1TR002345)
- 41st Kanae Foundation for the Promotion of Science Fellowship
- McDonnell Science Grant for Neuroscience
- ALS Association (2427)
- DIAN-TU Pharma Consortium
- Tau Consortium
- Alzheimer’s Association Research Fellowship (AARF-16-443265)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- tau protein, tau isoforms, tau phosphorylation, 4R tau, iPSC-derived neurons, human central nervous system, amyloid plaques, Alzheimer's disease, stable isotope labeling
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Brain, Cell Line, Cells, Cultured, Central Nervous System, Female, Humans, Kinetics, Male, Middle Aged, Biomarkers, tau Proteins, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
